Suanfarma unifies its industrial brands in a rebranding initiative under Suanfarma CDMO

Suanfarma CDMO

As Suanfarma, a leader in the B2B life science sector, we are excited to announce a strategic rebranding initiative. This move is designed to reinforce our position as a global player in healthcare, focusing on both the distribution of Active Pharmaceutical Ingredients (APIs) and our role as a Contract Development and Manufacturing Organization (CDMO) in producing these ingredients.

With this rebranding, our sites Cipan in Portugal and Rovereto in Italy are now recognized under the unified brand of Suanfarma CDMO. This unification enhances our visibility and flexibility in undertaking new projects, leveraging synergies between these two factories to optimize our operations.

Our rebranding is more than just a change in name or logo. It signifies a deeper transformation, emphasizing the integration of our sites into the larger Suanfarma global business model. We maintain our unwavering dedication to quality, a cornerstone of our success, and our core values continue to be supported by the commitment of our team to deliver high-quality solutions and services.

As Francisco Fernández, our CEO, states, “We have grown significantly in our CDMO capabilities, and now we want to showcase who we truly are.” At Suanfarma CDMO, we pride ourselves on adapting to customer needs in fermentation, purification, and chemical synthesis processes, handling small to large volumes.

In line with our new branding strategy, we are also introducing a new brand mantra: “At the Core of a Better Life.” This reflects our commitment to producing high-impact medicines that contribute to people’s health and well-being. We apply science to not only improve lives but also to care for the environment and support our partners’ development.

Daniel Rivero, our Industrial Director, emphasizes the importance of a strong corporate brand in today’s competitive business landscape. “The new brand architecture represents our commitment to corporate excellence, enhancing trust and recognition among global stakeholders,” he says.

This rebranding is a strategic opportunity for us to adopt a more corporate approach, aligning our brand with our CDMO capabilities and the innovative spirit of the industry. We aim to adapt to the evolving business landscape and set new standards for customer excellence, reinforcing our position as a key player in the life science sector.

Related news